JP2022512770A5 - - Google Patents
Info
- Publication number
- JP2022512770A5 JP2022512770A5 JP2021521472A JP2021521472A JP2022512770A5 JP 2022512770 A5 JP2022512770 A5 JP 2022512770A5 JP 2021521472 A JP2021521472 A JP 2021521472A JP 2021521472 A JP2021521472 A JP 2021521472A JP 2022512770 A5 JP2022512770 A5 JP 2022512770A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- cxcl
- amino acid
- recombinant
- peptide according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023198254A JP7798368B2 (ja) | 2018-10-22 | 2023-11-22 | Ｃｘｃｒ３の切断可能な活性化因子および使用方法 |
| JP2025145434A JP2025172140A (ja) | 2018-10-22 | 2025-09-02 | Ｃｘｃｒ３の切断可能な活性化因子および使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862748711P | 2018-10-22 | 2018-10-22 | |
| US62/748,711 | 2018-10-22 | ||
| PCT/US2019/056955 WO2020086400A1 (en) | 2018-10-22 | 2019-10-18 | Cleavable activators of cxcr3 and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198254A Division JP7798368B2 (ja) | 2018-10-22 | 2023-11-22 | Ｃｘｃｒ３の切断可能な活性化因子および使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022512770A JP2022512770A (ja) | 2022-02-07 |
| JP2022512770A5 true JP2022512770A5 (enExample) | 2022-10-17 |
| JP7426121B2 JP7426121B2 (ja) | 2024-02-01 |
Family
ID=70330587
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521472A Active JP7426121B2 (ja) | 2018-10-22 | 2019-10-18 | Ｃｘｃｒ３の切断可能な活性化因子および使用方法 |
| JP2023198254A Active JP7798368B2 (ja) | 2018-10-22 | 2023-11-22 | Ｃｘｃｒ３の切断可能な活性化因子および使用方法 |
| JP2025145434A Pending JP2025172140A (ja) | 2018-10-22 | 2025-09-02 | Ｃｘｃｒ３の切断可能な活性化因子および使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023198254A Active JP7798368B2 (ja) | 2018-10-22 | 2023-11-22 | Ｃｘｃｒ３の切断可能な活性化因子および使用方法 |
| JP2025145434A Pending JP2025172140A (ja) | 2018-10-22 | 2025-09-02 | Ｃｘｃｒ３の切断可能な活性化因子および使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US12110316B2 (enExample) |
| EP (1) | EP3870212A4 (enExample) |
| JP (3) | JP7426121B2 (enExample) |
| KR (1) | KR20210081372A (enExample) |
| CN (2) | CN120022352A (enExample) |
| AU (2) | AU2019365654B2 (enExample) |
| BR (1) | BR112021007414A2 (enExample) |
| CA (1) | CA3116325A1 (enExample) |
| IL (2) | IL324815A (enExample) |
| MX (1) | MX2021004496A (enExample) |
| SG (1) | SG11202103497WA (enExample) |
| WO (1) | WO2020086400A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210081372A (ko) * | 2018-10-22 | 2021-07-01 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 절단 가능한 cxcr3의 활성제 및 이의 사용 방법 |
| GB202208950D0 (en) * | 2022-06-17 | 2022-08-10 | Ucl Business Ltd | Treatment of the corneal endothelium |
| WO2024118744A2 (en) * | 2022-11-30 | 2024-06-06 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Coacervate formulations of cxcr3-activating peptides for controlled release in ophthalmic and topical treatments |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994292A (en) * | 1995-05-31 | 1999-11-30 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon-inducible protein 10 is a potent inhibitor of angiogenesis |
| MXPA00003885A (es) | 1997-10-22 | 2004-04-23 | Inst Genetics Llc | Quimiocinas con modificiaciones de la terminacion amino. |
| US20070116669A1 (en) * | 2002-09-13 | 2007-05-24 | Chemokine Therapeutics Corporation | Interferon-inducible protein-10 (IP-10 or CXCL10) chemokine analogs for the treatment of human diseases |
| GB2377444A (en) | 2001-04-09 | 2003-01-15 | Smithkline Beecham Plc | Chemokine-family polypeptide |
| IL164942A0 (en) * | 2004-10-31 | 2005-12-18 | Yeda Res & Dev | The use of a protease or a protease inhibitor for the manufacture of medicaments |
| US9180167B2 (en) | 2011-08-26 | 2015-11-10 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Activators of CXCR3 for the treatment of angiopathies of the eye |
| US8734775B2 (en) | 2011-08-26 | 2014-05-27 | University Of Pittsburgh | Chemokine derived peptides that bind with chemokine receptor CXCR3 and uses for chronic wound and angiogenesis inhibition treatments |
| AU2014306074B2 (en) * | 2013-08-05 | 2018-08-30 | Greenlight Biosciences, Inc. | Engineered proteins with a protease cleavage site |
| US9895419B2 (en) * | 2014-01-21 | 2018-02-20 | University of Pittsburgh—of the Commonwealth System of Higher Education | Goblet cell replacement therapy |
| ES2738582T3 (es) * | 2014-02-14 | 2020-01-23 | Immune Design Corp | Inmunoterapia del cáncer a través de combinación de inmunoestimulación local y sistémica |
| AU2017290828A1 (en) * | 2016-06-30 | 2019-01-24 | Virogin Biotech Canada Ltd | Pseudotyped oncolytic viral delivery of therapeutic polypeptides |
| JP7626577B2 (ja) | 2016-11-28 | 2025-02-07 | 中外製薬株式会社 | リガンド結合活性が調整可能なリガンド結合分子 |
| SG11201909160WA (en) * | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| KR20210081372A (ko) | 2018-10-22 | 2021-07-01 | 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 절단 가능한 cxcr3의 활성제 및 이의 사용 방법 |
-
2019
- 2019-10-18 KR KR1020217014758A patent/KR20210081372A/ko active Pending
- 2019-10-18 CN CN202510050400.1A patent/CN120022352A/zh active Pending
- 2019-10-18 IL IL324815A patent/IL324815A/en unknown
- 2019-10-18 IL IL282431A patent/IL282431B2/en unknown
- 2019-10-18 CA CA3116325A patent/CA3116325A1/en active Pending
- 2019-10-18 BR BR112021007414-7A patent/BR112021007414A2/pt unknown
- 2019-10-18 US US17/287,480 patent/US12110316B2/en active Active
- 2019-10-18 JP JP2021521472A patent/JP7426121B2/ja active Active
- 2019-10-18 EP EP19875282.6A patent/EP3870212A4/en active Pending
- 2019-10-18 CN CN201980069480.8A patent/CN113038965B/zh active Active
- 2019-10-18 MX MX2021004496A patent/MX2021004496A/es unknown
- 2019-10-18 WO PCT/US2019/056955 patent/WO2020086400A1/en not_active Ceased
- 2019-10-18 SG SG11202103497WA patent/SG11202103497WA/en unknown
- 2019-10-18 AU AU2019365654A patent/AU2019365654B2/en active Active
-
2023
- 2023-11-22 JP JP2023198254A patent/JP7798368B2/ja active Active
-
2024
- 2024-08-28 US US18/817,667 patent/US20250002549A1/en active Pending
-
2025
- 2025-02-08 AU AU2025200880A patent/AU2025200880A1/en active Pending
- 2025-09-02 JP JP2025145434A patent/JP2025172140A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108348580B (zh) | 白细胞介素-23受体的肽抑制剂以及其治疗炎症性疾病的用途 | |
| JP2022512770A5 (enExample) | ||
| US9682153B2 (en) | Polymer conjugates of therapeutic peptides | |
| AU2017295708B2 (en) | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| AU783479B2 (en) | Cell permeable peptides for inhibition of inflammatory reactions and methods of use | |
| CA2624175C (en) | Cgrp peptide antagonists and conjugates | |
| JP2025172140A5 (enExample) | ||
| US20040235746A1 (en) | Cell permeable peptides for inhibition of inflammatory reactions and methods of use | |
| EP2858661B1 (en) | Stabilized antiviral fusion helices | |
| DK3045183T3 (en) | PEGYLED APELIN AND APPLICATIONS THEREOF | |
| US20240270808A1 (en) | MANP Analogues | |
| JP7798368B2 (ja) | Ｃｘｃｒ３の切断可能な活性化因子および使用方法 | |
| US12241099B2 (en) | Peptide therapeutics for treating Alzheimer's disease and related conditions | |
| WO2020093789A1 (zh) | 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用 | |
| WO2020073825A1 (zh) | 一种改善生物活性蛋白性质的载体蛋白 | |
| CN115803338A (zh) | C型利尿钠肽及其治疗急性肺损伤的方法 | |
| JP2022547272A (ja) | Ｉｌ－２２の経口、直腸内、又は他の消化管関連の組成物及びそれを使用する方法 | |
| CN115605218A (zh) | 用于治疗大疱性表皮松解症的归巢肽引导的核心蛋白聚糖缀合物 | |
| HK40123732A (zh) | Cxcr3的可切割激活剂及其使用方法 | |
| CN110139659A (zh) | 用于治疗干燥综合征的肽 | |
| WO2025001976A1 (zh) | 新型补体抑制剂及其制备、应用和产品 | |
| CN116322738A (zh) | 血管加压素-2受体拮抗肽及其用途 | |
| WO2025226690A1 (en) | Methods and materials for using gc-a receptor activating peptides in combination with glp-1/gip receptor agonists | |
| WO2025133225A1 (en) | Pharmaceutical combination of peptide-gly and peptidylglycine alpha-amidating monooxygenase (pam) | |
| WO2022214649A1 (en) | Novel lipocalin muteins specific for connective tissue growth factor (ctgf) |